Loading…
Reported covered position: Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2026 · third_quarter · Q3
Issues regarding AI, financial management services, and workforce modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · RR
Source: Senate LDA
| CTIA - THE WIRELESSS ASSOCIATION |
| 8 |
| 2025–2026 |
| DAVITA, INC. | 8 | 2025–2026 |
| Fresenius Kabi | 8 | 2025–2026 |
| INTEL CORPORATION | 8 | 2025–2026 |
| LOWE'S COMPANIES INC | 8 | 2025–2026 |
| META PLATFORMS INC (FORMERLY FACEBOOK INC AND VARIOUS SUBSIDIARIES) | 8 | 2025–2026 |
| REPUBLIC SERVICES, INC. | 8 | 2025–2026 |
| TELNYX | 8 | 2025–2026 |
| VAPOR TECHNOLOGY ASSOCIATION | 8 | 2025–2026 |
| WALGREEN COMPANY | 8 | 2025–2026 |
| WALMART INC | 8 | 2025–2026 |
| ALLIANCE FOR SAFETY AND JUSTICE | 7 | 2025–2026 |
| CONSUMER TECHNOLOGY ASSOCIATION | 7 | 2025–2026 |
| EASTMAN CHEMICAL COMPANY | 7 | 2025–2026 |
| GOODRX | 7 | 2025–2026 |
| GOOGLE CLIENT SERVICES LLC | 7 | 2025–2026 |
| INTEGRAL AD SCIENCE | 7 | 2025 |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 7 | 2025–2026 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION | 7 | 2025–2026 |
| NATIONAL FOOTBALL LEAGUE | 7 | 2025–2026 |
| NATIONAL INSURANCE CRIME BUREAU | 7 | 2025–2026 |
| NETCHOICE | 7 | 2025–2026 |
| SANDOZ INC. | 7 | 2025–2026 |
| T-MOBILE USA, INC. | 7 | 2025–2026 |
| VIASAT, INC. | 7 | 2025–2026 |
| COMMONWEALTH LNG | 6 | 2025–2026 |
| FAMILIES AGAINST MANDATORY MINIMUMS | 6 | 2025 |
| FANDUEL GROUP | 6 | 2025–2026 |
| HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION | 6 | 2025 |
| PNC FINANCIAL INC. | 6 | 2025–2026 |
| PRUDENTIAL FINANCIAL INC | 6 | 2025–2026 |
| COHESITY, INC. | 5 | 2025–2026 |
| ESSITY NORTH AMERICA INC. | 5 | 2025–2026 |
| LKQ CORPORATION | 5 | 2025–2026 |
| TELGOO5 | 5 | 2025–2026 |
| TIN CAN UNTECHNOLOGIES, INC. | 5 | 2025–2026 |
| AMERICAN INNOVATORS NETWORK | 4 | 2026 |
| CATURUS ENERGY, LLC | 4 | 2026 |
| EXPEDIA GROUP | 4 | 2025 |
| NETFLIX | 4 | 2026 |
| RECYCLING LEADERSHIP COUNCIL | 4 | 2026 |
| SNCF AMERICA INC | 4 | 2025–2026 |
| DOORDASH | 2 | 2026 |
| WORKDAY, INC. | 2 | 2026 |
| SKYDIO, INC. | 1 | 2026 |
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
HR 4105 (Veterans Energy Transition Act)
HR 4105 (Veterans Energy Transition Act)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
High-Capacity Grid Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
High-Capacity Grid Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; S. 3947 REWIRE Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Limiting Liability for Critical Infrastructure Manufacturers Act
Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION · Firm: S-3 GROUP
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Preserve Access to Affordable Generics and Biosimilars Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernizational of prescribing information for physicians and pharmacists; Increasing Trasnparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Increasing Transparency in Generic Drug Applications Act
Client: VIATRIS (MYLAN, INC) · Firm: S-3 GROUP
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues regarding AI, financial management services, and workforce modernization
CATURUS ENERGY, LLC via S-3 GROUP
2026 · third_quarter · Q3
Issues related to securing a permit to export liquified natural gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN INNOVATORS NETWORK via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the regulation of artificial intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECYCLING LEADERSHIP COUNCIL via S-3 GROUP
2026 · third_quarter · Q3
Issues pertaining to advanced recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to federal data privacy, children's online privacy, and regulation of artificial intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSITY NORTH AMERICA INC. via S-3 GROUP
2026 · third_quarter · Q3
Advocacy related to product regulatory issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIN CAN UNTECHNOLOGIES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the regulation of telecommunication services
Filing targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to online sports gaming
Issues relating to tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to spectrum policy and satellite communications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to privacy
Issues related to trade
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via S-3 GROUP
2026 · third_quarter · Q3
Issues related to infant formula
Proposals to reform domestic and international tax structures
Equitable Access to Community Pharmacist Services Act
Issues related to the FCC; issues related to implementation of the Telephone Robocall Abuse Criminal Enforcement and Deterrence (TRACED) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · third_quarter · Q3
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL LEGAL FINANCE ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to commercial legal finance
Issues related to commercial legal finance
Issues related to commercial legal finance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to trade and tariffs
Issues related to support for domestic chipmakers in NDAA
Issues related to Inter Partes Review and patent litigation at the ITC
AMERICAN EXPLORATION & PRODUCTION COUNCIL via S-3 GROUP
2026 · third_quarter · Q3
Monitor issues and legislation to support the resonsible production of American oil and gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANDOZ INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
General educational meetings on policy issues impacting tech platforms
Monitor issues related to consumer data privacy, and children's privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
S. 448/H.R. 4128 (CIRCUIT Act), and future opportunities (Recon 3.0), focusing on expansion of the 45X tax credit
Section 232 tariffs, including measures affecting steel, aluminum, semiconductors, and critical minerals, as well as actions related to reciprocal tariffs; advanced NEMA's tariff incentive proposal to accelerate energy and domestic manufacturing priorities.
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
EASTMAN CHEMICAL COMPANY via S-3 GROUP
2026 · third_quarter · Q3
Advice and assistance on chemical industry and recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to childrens privacy, including Kids Online Safety Act; Reducing Exploitative Social Media Exposure for Teens (RESET) Act, and App Store Accountability Act.
Issues related to the regulation of technology, including: antitrust, Section 230, childrens privacy (Kids Online Safety Act; Reducing Exploitative Social Media Exposure for Teens (RESET) Act), App Store Accountability Act, and artificial intelligence.
The American Innovation and Choice Online Act (AICOA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
META PLATFORMS, INC. (FORMERLY FACEBOOK, INC. AND VARIOUS SUBSIDIARIES) via S-3 GROUP
2026 · third_quarter · Q3
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · third_quarter · Q3
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL FOOTBALL LEAGUE via S-3 GROUP
2026 · third_quarter · Q3
Legislative and regulatory issues affecting the professional sports industry, such as player health and safety, antitrust, intellectual property, and sports betting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES, LLC via S-3 GROUP
2026 · third_quarter · Q3
Issues related to human trafficking efforts and criminal justice reform
Issues related to intellectual property enforcement
Issues related to competition in online services
T-MOBILE USA, INC. via S-3 GROUP
2026 · third_quarter · Q3
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · fourth_quarter · RR
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
CATURUS ENERGY, LLC via S-3 GROUP
2026 · second_quarter · Q2
Issues related to securing a permit to export liquified natural gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATURUS ENERGY, LLC via S-3 GROUP
2026 · first_quarter · Q1
Issues related to securing a permit to export liquified natural gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATURUS ENERGY, LLC via S-3 GROUP
2026 · first_quarter · RR
Issues related to securing a permit to extort liquified natural gas
AMERICAN INNOVATORS NETWORK via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the regulation of artificial intelligence
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · 2A
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RECYCLING LEADERSHIP COUNCIL via S-3 GROUP
2026 · second_quarter · Q2
Issues pertaining to advanced recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to competition in the entertainment services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSITY NORTH AMERICA INC. via S-3 GROUP
2026 · second_quarter · Q2
Advocacy related to product regulatory issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to privacy, data security, and funding
Issues related to privacy, data security, and funding
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIN CAN UNTECHNOLOGIES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to the regulation of telecommunication services
Filing targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues relating to tax
Issues related to online sports gaming
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to spectrum policy and satellite communications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via S-3 GROUP
2026 · second_quarter · Q2
Proposals to reform domestic and international tax structures
Equitable Access to Community Pharmacist Services Act
Equitable Access to Community Pharmacist Services Act
Issues related to the FCC; issues related to implementation of the Telephone Robocall Abuse Criminal Enforcement and Deterrence (TRACED) Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRIGHTHOUSE SERVICES LLC via S-3 GROUP
2026 · second_quarter · Q2
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
REPUBLIC SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Issues related to waste management, recycling and circularity, environmental policy, and taxation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL INSURANCE CRIME BUREAU via S-3 GROUP
2026 · second_quarter · 2T
Issues related to consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to dialysis payment policy, including End Stage Renal Disease (ESRD) Perspective Payment System (PPS)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN PSYCHOLOGICAL ASSOCIATION SERVICES, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to reimbursement for psychologists in designated health professional shortage areas; and issues related to reimbursement for psychological and neuropsychological testing in Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to higher education
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LOWE'S COMPANIES INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues related to corporate tax reform
Issues related to corporate tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VAPOR TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the regulation of vapor products
Issues relating to the regulation of vapor products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTERNATIONAL LEGAL FINANCE ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to commercial legal finance
Issues related to commercial legal finance
Issues related to commercial legal finance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Issues related to the provider status of pharmacists under Medicare Part B
Issues related to pharmacy, pharmacist provider status, pharmacy benefit managers, Medicare reimbursement, and pharmaceutical supply chain transparency
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR SAFETY AND JUSTICE via S-3 GROUP
2026 · second_quarter · 2T
Issues related to policies/programs that will increase community safety and improve public health, with a focus on meeting the needs of crime survivors, people returning home from prison, and community-based organizations that support them
Issues related to policies/programs that will increase community safety and improve public health, with a focus on meeting the needs of crime survivors, people returning home from prison, and community-based organizations that support them
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTEL CORPORATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to support for domestic chipmakers in NDAA
Issues related to semiconductor competitiveness
Issues related to trade and tariffs
AMERICAN EXPLORATION & PRODUCTION COUNCIL via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues and legislation to support the resonsible production of American oil and gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANDOZ INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues and legislative proposals on biosimilars and generics medicines, including but not limited to generics and biosimilar sustainability, pharmaceutical supply chain security, drug shortages, interchangeability, patent litigation, and PBM reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Issues pertaining to policy matters impacting labor, independent workers, gig economy, consumer issues and food, restaurant, small businesses
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER TECHNOLOGY ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Monitor issues related to consumer data privacy, and children's privacy
General educational meetings on policy issues impacting tech platforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
S. 448/H.R. 4128 (CIRCUIT Act), and future opportunities (Recon 3.0), focusing on expansion of the 45X tax credit
H.R. 4194 Limiting Liability for Critical Infrastructure Manufacturers Act (Wildfire liability protections for manufacturers of critical grid components)
Section 232 tariffs, including measures affecting steel, aluminum, semiconductors, and critical minerals, as well as actions related to reciprocal tariffs; advanced NEMA's tariff incentive proposal to accelerate energy and domestic manufacturing priorities.
EASTMAN CHEMICAL COMPANY via S-3 GROUP
2026 · second_quarter · Q2
Advice and assistance on chemical industry and recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to childrens privacy, including Kids Online Safety Act; Reducing Exploitative Social Media Exposure for Teens (RESET) Act, and App Store Accountability Act.
Issues related to the regulation of technology, including: antitrust, Section 230, childrens privacy (Kids Online Safety Act; Reducing Exploitative Social Media Exposure for Teens (RESET) Act), App Store Accountability Act, and artificial intelligence.
The American Innovation and Choice Online Act (AICOA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
META PLATFORMS, INC. (FORMERLY FACEBOOK, INC. AND VARIOUS SUBSIDIARIES) via S-3 GROUP
2026 · second_quarter · Q2
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Issues related to privacy, security data legislation, discussion regarding cyber security, data security, encryption, youth safety, and platform integrity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CTIA THE WIRELESS ASSOCIATION via S-3 GROUP
2026 · second_quarter · Q2
Issues related to wireless policy, including spectrum, broadband funding, 5G, and privacy; issues related to the use of contraband phones in correctional facilities; issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL FOOTBALL LEAGUE via S-3 GROUP
2026 · second_quarter · Q2
Legislative and regulatory issues affecting the professional sports industry, such as player health and safety, antitrust, intellectual property, and sports betting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GOOGLE CLIENT SERVICES, LLC via S-3 GROUP
2026 · second_quarter · Q2
Issues related to human trafficking efforts and criminal justice reform
Issues related to intellectual property enforcement
Issues related to funding in Appropriations bills and internet governance
T-MOBILE USA, INC. via S-3 GROUP
2026 · second_quarter · Q2
Issues relating to the repurposing of spectrum
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COMMONWEALTH LNG via S-3 GROUP
2026 · first_quarter · 1T
Issues related to securing a permit to export liquified natural gas
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN INNOVATORS NETWORK via S-3 GROUP
2026 · first_quarter · Q1
Legislation related to AI preemption
Legislation related to AI preemption
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN INNOVATORS NETWORK via S-3 GROUP
2026 · first_quarter · RR
Legislation related to AI preemption
Legislation related to AI preemption
RECYCLING LEADERSHIP COUNCIL via S-3 GROUP
2026 · first_quarter · Q1
Issues pertaining to advanced recycling
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to competition in the entertainment services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSITY NORTH AMERICA INC. via S-3 GROUP
2026 · first_quarter · Q1
Advocacy related to product regulatory issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to auto parts market
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to privacy and data security
Issues related to privacy, data security, and funding
Issues related to privacy, data security, and funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIN CAN UNTECHNOLOGIES, INC. via S-3 GROUP
2026 · first_quarter · Q1
Issues related to the regulation of telecommunication services
Filing targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues relating to tax
Issues related to online sports gaming
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding lower prescription drug prices for patients
Issues regarding lower prescription drug prices for patients
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to spectrum policy
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
PNC FINANCIAL INC. via S-3 GROUP
2026 · first_quarter · Q1
Monitor issues impacting the financial services industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIATRIS (MYLAN, INC) via S-3 GROUP
2026 · first_quarter · Q1
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to trade
Issues related to privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Equitable Access to Community Pharmacist Services Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to R&D tax credit
Issues related to funding for CHIPS Act
Issues related to semiconductor competitiveness
Issues in support for STEM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding in Appropriations bills and internet governance
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to U.S. manufacturing and use of unmanned aircraft systems, including appropriations and legislation affecting public safety, homeland security, and national security.
Issues related to infant formula
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
General issues related to retirement planning, including annuities and life insurance; taxation; cybersecurity; and consumer privacy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding for CHIPS Act
Issues related to R&D tax credit
Issues in support for STEM
Issues related to Inter Partes Review and patent litigation at the ITC
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 4105 (Veterans Energy Transition Act)
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to competition in online services
Issues related to privacy and data security
Filing targets: HOUSE OF REPRESENTATIVES, SENATE